Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Novel PRGN-2012 AdenoVerse™ Immunotherapy Discovered for Recurrent Respiratory Papillomatosis

Precigen discovered novel PRGN-2012 AdenoVerse™ Immunotherapy designed specifically for patients suffering from recurrent respiratory papillomatosis. 

The PRGN-2012 AdenoVerse™ Immunotherapy utilises advanced antigen design techniques and leverages gorilla adenovector technology to trigger targeted immune responses against cells infected with human papillomavirus type 6 (HPV 6) or HPV type 11 (HPV 11). 

Gorilla adenovectors offer several significant benefits, such as the capacity for repeated administration, inability to replicate in the body, and the ability to deliver substantial genetic material payloads. In preclinical studies, PRGN-2012 has exhibited robust and highly targeted immune responses against HPV 6 and HPV 11. 

Recurrent respiratory papillomatosis (RRP) is a rare and challenging disease affecting the upper and lower respiratory tracts. It is characterised by the growth of neoplastic (tumour-like) papillomas caused by infection with HPV 6 or HPV 11. Currently there is currently no cure for RRP. 

Recurrence of papillomas after surgery is very common, and removal and monitoring of the disease require repeated procedures, exposing patients to anaesthetic and surgical risks and emotional stress.

US Food and Drug Administration (FDA) grants breakthrough therapy designation for the first-in-class investigational PRGN-2012 AdenoVerse immunotherapy.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024